BIIBBiogen Inc

$339.19
$2.09 (1%)

Biogen Inc (BIIB) Stock Analysis

Create a FREE Account to View Full BIIB Stock Report

Biogen Inc (BIIB) Analyst Forecast

Next 12 months ➝Current Price$339.1952-week High$374.9952-week Low$215.77MEAN$327.09-3.57%HIGH$410.00+20.88%LOW$235.00-30.72%
  • Last Price$339.19
  • Previous Close$337.10
  • Change $2.09
  • Open$338.00
  • Volume724,387
  • Avg. Volume (100-day)2,074,420
  • Market Capitalization$59.04B
  • Days Range $335.42 - $340.80
  • 52-week Range $215.77 - $374.99
  • Dividend Yield
  • Ex. Dividend Date
  • P-E10.7
  • EPS31.46
  • Earnings Date04/22/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta2.275
  • PEG Ratio1.25
  • Volatility0.62
  • Average True Range0.03
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.